Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

(Reuters) -The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 who are at higher risk for ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing.

Cambridge: Moderna, Inc. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Kennedy has made the point repeatedly in congressional testimony and in his response to an ongoing measles outbreak. He has said he believes reassuring Americans that vaccination is up to them, and ...

Note that some links may require registration or subscription. The United Kingdom's Food Standards Agency says that certain ...

Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...